PT 141 - Bremelanotide
US$ 23.23
ghk-cu clinical trial humans Frontiers GHK-Cu - GenScript
Description
Subcutaneous injection (compounded prescription) Published clinical protocols report typical dose ranges of 1 to 3 mg subcutaneously, administered daily or several times per week, adjusted for the individual patient by their prescribing provider
DoD guidance mandates that all service members be tested at least annually, and many branches exceed this
Investigation 102, 874880
With ongoing support, weight loss often follows shortly after
